eligibility_summary
Include: Able to consent, severe asthma per ATS/ERS/GINA, blood eos ≥150/µL at screening or ≥300/µL in past 12 months, ≥1 exacerbation in prior year on high‑dose ICS+LABA ± LAMA or systemic steroids, eligible for benralizumab. Exclude: exacerbation within 6 wks needing ER/hospital, prior interfering biologics, pregnant/nursing or women of childbearing potential, malignancy/serious comorbidity, non‑asthma eosinophilia (HES, EGPA, EoE).
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Benralizumab, a humanized afucosylated IgG1 monoclonal antibody (biologic) targeting interleukin‑5 receptor alpha (IL‑5Rα), 30 mg SC q4w ×3 then q8w, compared with standard care. Mechanism: blocks IL‑5/IL‑5R signaling and induces Fc-mediated ADCC, depleting eosinophils (and basophils), thereby reducing type 2 eosinophilic inflammation and potentially reversing airway remodeling. Targets: cells—eosinophils (primary), basophils, pathways—IL‑5/IL‑5R axis and downstream type‑2 inflammatory cascade. Evaluations focus on airway smooth muscle, goblet cells, basement membrane/lamina reticularis, biomarkers include blood eosinophils, FeNO, IgE, with exploratory ILC2/IL‑33/TSLP.